Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dopamine + dextrose is a sterile premixed intravenous solution containing dopamine hydrochloride (a catecholamine inotropic/vasopressor agent) dissolved in 5% dextrose as a stabilizing vehicle and calorie source. Dopamine acts primarily as a sympathomimetic amine with dose-dependent agonist activity on dopamine (D1, D2), beta-1, and at higher doses, alpha-1 adrenergic receptors. It increases cardiac contractility and output (inotropy), improves renal and mesenteric blood flow, and at higher doses causes vasoconstriction to treat hypotension. The addition of dextrose provides calories and prevents hypoglycemia. The main clinical uses are for the correction of hemodynamic imbalances seen in shock (due to myocardial infarction, trauma, sepsis, open-heart surgery, renal failure), low cardiac output, and as adjunct in congestive heart failure or post-operative states requiring inotropic support[1][2][4][8][10][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dopamine + dextrose.